Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C

NCT00144469 is registered in ClinicalTrials.gov with Chugai Pharmaceutical as lead sponsor.

NCT NCT00144469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C
Lead sponsor
Chugai Pharmaceutical
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2002
Completion date
March 31, 2005
Enrollment
300 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c